News and Trends 14 Jul 2022 Agomab bags $114 million in thriving regenerative medicine sector The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million to hit $114 million. This Pfizer-led financing round extension is just the latest sign that the emerging field of regenerative medicine is coming to the fore. Agomab has embarked on an ambitious path to redefine how we understand regenerative medicine […] July 14, 2022 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
Expert Advice 2 May 2022 Chief Business Officers: Shedding Light on Biotech’s Dealmakers In addition to helping patients, biotech companies need to focus on the commercial potential of their work. Stephanie Bewick at Destiny Pharma outlines her experiences of how a Chief Business Officer maximizes their company’s commercial appeal and lands deals in the biotech industry. Stephanie Bewick began her career as an academic researcher before spending more […] May 2, 2022 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 11 Mar 2022 Microbiome Space in Spotlight as Microbiotica Sets Funding Record Competition is heating up in the microbiome niche as UK-based Microbiotica raised €60M (£50M) in a Series B round to advance two candidates designed to treat cancer and ulcerative colitis. Microbiotica’s financing sets a record in Europe for microbiome specialist biotechs. The round was co-led by Sweden’s Flerie Invest and China-based Tencent, and was supported […] March 11, 2022 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2022 Reforms of EU Clinical Trial Regulations Bring Cautious Optimism The EU’s clinical trial regulations received a major overhaul at the end of January 2022 to make trials easier to run across EU member states. It may bring some short-term chaos, industry insiders say, but down the road it is likely to pay off. At the start of February, the EU’s new Clinical Trials Regulation […] February 8, 2022 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
Expert Advice 24 Jan 2022 Transitioning from Academia to Chief Scientific Officer in the Biotech Industry Academics with a drive to turn their research into commercial products often end up in the position of Chief Scientific Officer at a biotech company. Kees Melief shares his own personal experience transitioning from academia to industry. After his retirement as an academic researcher at Leiden University, Cornelis ‘Kees’ Melief founded and became the Chief […] January 24, 2022 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2021 Despite New Approvals, Covid-19 Treatments Lag Behind Vaccines The EU recently added two drugs to its list of approved Covid-19 treatments. Yet with vaccines often in the spotlight, treatment options available to doctors remain few. Earlier this month, the European Commission gave its stamp of approval to two antibody treatments for Covid-19: regdanvimab from the South Korean firm Celltrion Healthcare, and a blend […] November 25, 2021 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2021 Evotec IPO Hints At Stabilizing Investor Interest In Biotech Stocks German life sciences heavyweight Evotec raised around €376M ($435M) in its US debut on the Nasdaq last week, fueling tentative hopes of renewed investor interest in biotech stocks after a rollercoaster year. The company downsized its initial IPO target of around €500M ($576M) by offering fewer shares than initially planned. This is widely seen as […] November 10, 2021 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
Expert Advice 1 Nov 2021 “The Board of Directors Should Let the CEO Run the Company” The relationship between the board and the CEO can be essential to the success of a life sciences company. Drawing from his experience at both sides, Alan Levy shares his advice on how to make that relationship work. Once known as the person who introduced portable defibrillators on the market in the 1990s, Alan Levy […] November 1, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2021 Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial Last week, the French vaccine maker Valneva announced promising phase III trial results of its inactivated Covid-19 vaccine: a well-established technology that could confer broader immunity to the virus than shots currently on the market. Valneva’s vaccine candidate consists of a killed or ‘inactivated’ version of SARS-CoV-2, the virus responsible for Covid-19. The vaccine was […] October 26, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2021 Third-Generation DNA Sequencing Shines with Oxford Nanopore’s IPO Oxford Nanopore Technologies, until recently one of very few unicorns in the European biotech industry, had a stellar IPO on the London Stock Exchange late last month. This is ushering in a whole new generation of DNA sequencing, genetics research, and diagnostics. During the first day of the IPO, which bagged the firm over €400M […] October 15, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2021 Longevity Foundation to Fund Geroscience Research with €860M The newly-created Longevity Science Foundation aims to extend the human lifespan to more than 120 years by channeling over €860M ($1B) into early-stage geroscience research in the next decade. Experts say that’s a worthy if complex goal. Based in Zug, Switzerland, the Longevity Science Foundation will prioritize four areas of research: personalized medicine, therapeutics, artificial […] October 11, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2021 Non-Viral Gene Therapies Get €51M Boost, Though Challenges Remain Although most gene therapy still relies on non-infectious viral vectors for delivery, a recent venture financing round for the Swiss company Anjarium Biosciences has shone the spotlight on alternative vectors, including lipid nanoparticles and electric pulses. Last month, Anjarium Biosciences raised €51M (CHF55.5M) in a Series A financing round to advance its gene delivery system […] October 4, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email